Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2015-05-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.2015.1041500PMID 25945893PMCID PMC4677053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.

  2015cited by this paper
• Cachexia: clinical features when inflammation drives malnutrition

  2015cited by this paper
• Ghrelin Augments the Expressions and Secretions of Proinflammatory Adipokines, VEGF120 and MCP‐1, in Differentiated 3T3‐L1 Adipocytes

  2015cited by this paper
• An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelin

  2015cited by this paper
• Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved

  2015cited by this paper
• Subgroup analysis of ECOG2 patients from ROMANA 2: A phase III study of anamorelin in NSCLC patients with cachexia.

  2014cited by this paper
• Rikkunshito, a ghrelin potentiator, ameliorates anorexia–cachexia syndrome

  2014cited by this paper
• Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile

  2014influential reference
• Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients

  2014cited by this paper
• Ghrelin signalling in β‐cells regulates insulin secretion and blood glucose

  2014cited by this paper
• Mechanisms in endocrinology: regulation of glucose metabolism by the ghrelin system: multiple players and multiple actions.

  2014cited by this paper
• Preclinical gastrointestinal prokinetic efficacy and endocrine effects of the ghrelin mimetic RM-131.

  2014cited by this paper
• Anamorelin for the treatment of cancer anorexia-cachexia: Baseline characteristics from three phase III clinical trials (the ROMANA program).

  2014cited by this paper
• P-0205CYTOKINES, DEPRESSION AND ANXIETY IN COLORECTAL CANCER PATIENTS IN DIFFERENT STAGES OF THE ANTITUMOR THERAPY

  2014cited by this paper
• 1483O_PRANAMORELIN FOR THE TREATMENT OF CANCER ANOREXIA-CACHEXIA IN NSCLC: RESULTS FROM THE PHASE 3 STUDIES ROMANA 1 AND 2

  2014cited by this paper
• Anamorelin for the Treatment of Cancer Anorexia-Cachexia in Advanced NSCLC Patients: Results From ROMANA 1, a Pivotal Phase 3 Study

  2014influential reference
• Inhibition of cisplatin-induced lipid catabolism and weight loss by ghrelin in male mice.

  2013cited by this paper
• Evaluation of quality of life from a phase II study of anamorelin HCl in NSCLC patients.

  2013cited by this paper
• The potential of ghrelin in the treatment of cancer cachexia

  2013cited by this paper
• Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model

  2013cited by this paper
• Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial.

  2013cited by this paper
• Diaphragm and ventilatory dysfunction during cancer cachexia

  2013cited by this paper
• Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index.

  2013cited by this paper
• Acylated and unacylated ghrelin impair skeletal muscle atrophy in mice.

  2013cited by this paper
• Understanding the mechanisms and treatment options in cancer cachexia

  2013cited by this paper
• Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial.

  2013cited by this paper
• The Role of Thalidomide and Placebo for the Treatment of Cancer-Related Anorexia-Cachexia Symptoms: Results of a Double-Blind Placebo-Controlled Randomized Study

  2012cited by this paper
• Predicting survival in cancer patients: the role of cachexia and hormonal, nutritional and inflammatory markers

  2012cited by this paper
• Pathophysiological Role of Hormones and Cytokines in Cancer Cachexia

  2012cited by this paper
• Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

  2012cited by this paper
• Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients

  2012cited by this paper
• Cancer Cachexia: Mechanisms and Clinical Implications

  2011cited by this paper
• Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia

  2011cited by this paper
• Definition and classification of cancer cachexia: an international consensus.

  2011cited by this paper
• RACK1, A multifaceted scaffolding protein: Structure and function

  2011cited by this paper
• Ghrelin for cachexia

  2010cited by this paper
• Genetic suppression of ghrelin receptors activates brown adipocyte function and decreases fat storage in rats.

  2010cited by this paper
• Cancer Cachexia: Traditional Therapies and Novel Molecular Mechanism-Based Approaches to Treatment

  2010cited by this paper
• Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis.

  2010cited by this paper
• Cachexia as a major underestimated and unmet medical need: facts and numbers

  2010cited by this paper
• Treatment of Cachexia in Oncology

  2010cited by this paper
• Effects by daily long term provision of ghrelin to unselected weight‐losing cancer patients

  2010cited by this paper
• Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.

  2009cited by this paper
• Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

  2008cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008cited by this paper
• PRECLINICAL STUDY: Systemic administration of ghrelin induces conditioned place preference and stimulates accumbal dopamine

  2008cited by this paper
• Characterization of adult ghrelin and ghrelin receptor knockout mice under positive and negative energy balance.

  2008cited by this paper
• Cachexia Worsens Prognosis in Patients with Resectable Pancreatic Cancer

  2008cited by this paper
• Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism, and Physical Functioning

  2007cited by this paper
• Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers.

  2007cited by this paper
• Expression of ghrelin receptor mRNA in the rat and the mouse brain

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Measuring fatigue in cancer: a review of assessment scales

  2006cited by this paper
• Ghrelin: structure and function.

  2005cited by this paper
• Growth hormone releasing hormone plasmid supplementation, a potential treatment for cancer cachexia, does not increase tumor growth in nude mice

  2005cited by this paper
• Identification of ghrelin and its receptor in neurons of the rat arcuate nucleus.

  2005cited by this paper
• Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin.

  2004cited by this paper
• Ghrelin--a hormone with multiple functions.

  2004cited by this paper
• [Experiences with dronabinol (delta-tetrahydrocannabinol) in oncological patients with anorexia-cachexia syndrome. Illustration of clinical problems and therapy based on 2 case reports].

  2004cited by this paper
• Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells.

  2004cited by this paper
• [Experiences with dronabinol (delta-tetrahydrocannabinol) in oncological patients with anorexia-cachexia syndrome. Illustration of clinical problems and therapy based on 2 case reports].

  2004cited by this paper
• Ghrelin Inhibits Proinflammatory Responses and Nuclear Factor-κB Activation in Human Endothelial Cells

  2004cited by this paper
• Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial.

  2004cited by this paper
• The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis.

  2003cited by this paper
• The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans.

  2002cited by this paper
• Ghrelin strongly stimulates growth hormone release in humans.

  2000cited by this paper
• Artificial Nutrition in Cancer Patients: Which Route, What Composition?

  1999cited by this paper
• Co-Localization of Growth Hormone Secretagogue Receptor and NPY mRNA in the Arcuate Nucleus of the Rat

  1999cited by this paper
• Ghrelin is a growth-hormone-releasing acylated peptide from stomach

  1999cited by this paper
• Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.

  1997cited by this paper
• Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues.

  1997cited by this paper
• Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study.

  1993cited by this paper
• Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

  1980cited by this paper

• Cancer cachexia: molecular basis and therapeutic advances

  2026cites this paper
• Wide-range and high-throughput quantification of anamorelin in human plasma using ultra-high-performance liquid chromatography coupled to tandem mass spectrometry.

  2025cites this paper
• Spirocyclopentane as a Novel Scaffold for Potent Ghrelin Receptor Full Agonists.

  2025cites this paper
• Design, Biological Characterization, and Discovery of Capromorelin Derivatives as Oral Growth Hormone Secretagogue Receptor Type 1a Agonist for the Treatment of Growth Hormone Deficiency.

  2025cites this paper
• Anamorelin Induced Acute Hyperglycemia in a Patient with Advanced Pancreatic Cancer and Diabetes: A Case Report.

  2024cites this paper
• Association of the modified Glasgow prognostic score and prognostic nutritional index with duration of oral anamorelin administration in patients with cancer cachexia: a retrospective cohort study.

  2024cites this paper
• Determination of anamorelin concentration in human plasma using a simple high-performance liquid chromatography-ultraviolet detection method.

  2024cites this paper
• Unlocking the Potential of Obestatin: A Novel Peptide Intervention for Skeletal Muscle Regeneration and Prevention of Atrophy

  2024cites this paper
• Screening study of anti-emetics to improve GDF15-induced malaise and anorexia: Implications for emesis control.

  2023cites this paper
• Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study

  2023cites this paper
• Synthetic Approaches to the New Drugs Approved During 2021.

  2023cites this paper
• Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study

  2022cites this paper
• Binding Domain Characterization of Growth Hormone Secretagogue Receptor

  2022cites this paper
• Assessment and nonpharmacological management for patients with cancer anorexia-cachexia syndrome: a best practice implementation project.

  2022cites this paper
• Anamorelin combined with physical activity, and nutritional counseling for cancer-related fatigue: a preliminary study

  2021cites this paper
• Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren

  2021cites this paper
• Growth hormone secretagogue receptor‐1a mediates ghrelin's effects on attenuating tumour‐induced loss of muscle strength but not muscle mass

  2021influential citation
• Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors

  2020cites this paper
• Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol

  2020cites this paper
• Investigational drugs for the treatment of cancer cachexia: a focus on phase I and phase II clinical trials

  2019cites this paper
• Cachexia/Anorexia and Feeding Difficulties

  2019cites this paper
• Ghrelin‐mediated improvements in the metabolic phenotype in the R6/2 mouse model of Huntington's disease

  2019cites this paper
• The Role of the Small Bowel in Unintentional Weight Loss after Treatment of Upper Gastrointestinal Cancers

  2019cites this paper
• Ghrelin as a Promising Therapeutic Option for Cancer Cachexia

  2018cites this paper
• Z‐505 hydrochloride ameliorates chemotherapy‐induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a

  2018cites this paper
• Medicinal cannabinoids in palliative care

  2018cites this paper
• Differential functional selectivity and downstream signaling bias of ghrelin receptor antagonists and inverse agonists

  2018cites this paper
• Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia—Review and Expert Opinion

  2018cites this paper
• An Overview of Muscle Atrophy.

  2018cites this paper
• Cachexia / Anorexia and Feeding Difficulties

  2018cites this paper
• Ghrelin system signalling in appetite and reward: in vitro and in vivo perspectives

  2018cites this paper
• Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists.

  2018cites this paper
• Molecular mechanism of sarcopenia and cachexia: recent research advances

  2017cites this paper
• Anamorelin (ONO‐7643) for the treatment of patients with non–small cell lung cancer and cachexia: Results from a randomized, double‐blind, placebo‐controlled, multicenter study of Japanese patients (ONO‐7643‐04)

  2017cites this paper
• The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.

  2017cites this paper
• Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice.

  2017cites this paper
• Cancer-induced muscle wasting: latest findings in prevention and treatment

  2017cites this paper
• Obesity Paradox in Lung Cancer Prognosis: Evolving Biological Insights and Clinical Implications

  2017influential citation
• Plasma Ghrelin Levels Are Associated with Anorexia but Not Cachexia in Patients with NSCLC

  2017influential citation
• Cancer Cachexia: Cause, Diagnosis, and Treatment.

  2017cites this paper
• From Belly to Brain: Targeting the Ghrelin Receptor in Appetite and Food Intake Regulation

  2017cites this paper
• Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis

  2017cites this paper
• Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

  2016cites this paper
• Undernutrition, Inflammation and Catabolic Illness, and Growth Hormone Secretion

  2016cites this paper
• Pharmacological management update: Clinical significance of anamorelin clinical trials for the treatment of cancer cachexia in advanced cancer patients

  2016cites this paper
• Ghrelin for the management of cachexia associated with cancer.

  2016cites this paper
• STAT3 in the systemic inflammation of cancer cachexia.

  2016cites this paper
• Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer.

  2016cites this paper
• Palliative Care of Cancer in the Older Patient

  2016cites this paper
• A Novel Non-Peptidic Agonist of the Ghrelin Receptor with Orexigenic Activity In vivo

  2016cites this paper
• Clinical results in cachexia therapeutics

  2016cites this paper
• Palliative Care in Older Patients With Cancer.

  2015cites this paper